Bristol-Myers Squibb Co (BRM) Stock Price & News

Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2025, 69% of the company's revenues came from the United States. The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000. Wikipedia

About Bristol-Myers Squibb Co

CEOChris Boerner

Employees32.5 мян

Founded1887

HeadquartersНью-Йорк хот, Нью-Йорк Муж Улс, Америкийн Нэгдсэн Улс

SectorPharmaceutical industry

Websitebms.com

Revenue

Net income

All values in USD	2025 оны 9-р сар	2025 оны 12-р сар	2026 оны 3-р сар	2026 оны 6-р сар
Revenue	12.22 тэрбум	12.50 тэрбум	11.49 тэрбум	12.97 тэрбум
Cost of goods sold	3.31 тэрбум	3.51 тэрбум	3.41 тэрбум	3.71 тэрбум
Cost of revenue	3.31 тэрбум	3.51 тэрбум	3.41 тэрбум	3.71 тэрбум
Research and development expenses	2.43 тэрбум	2.56 тэрбум	2.24 тэрбум	2.54 тэрбум
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	1.79 тэрбум	2.09 тэрбум	1.61 тэрбум	1.82 тэрбум
Operating expense	5.05 тэрбум	5.47 тэрбум	4.28 тэрбум	4.80 тэрбум
Total operating expenses	8.36 тэрбум	8.98 тэрбум	7.69 тэрбум	8.51 тэрбум
Operating income	3.86 тэрбум	3.52 тэрбум	3.80 тэрбум	4.46 тэрбум
Other non operating income	529.00 сая	544.00 сая	125.00 сая	106.00 сая
EBT including unusual items	3.11 тэрбум	1.47 тэрбум	3.24 тэрбум	4.09 тэрбум
EBT excluding unusual items	4.07 тэрбум	3.86 тэрбум	3.65 тэрбум	4.35 тэрбум
Income tax expense	919.00 сая	384.00 сая	561.00 сая	770.00 сая
Effective tax rate	29.51%	26.12%	17.32%	18.84%
Other operating expenses	-	-	-	-
Net income	2.20 тэрбум	1.09 тэрбум	2.68 тэрбум	3.32 тэрбум
Net profit margin	18.01%	8.69%	23.30%	25.57%
Earnings per share	1.63	1.26	1.58	2.04
Interest and investment income	161.00 сая	148.00 сая	104.00 сая	101.00 сая
Interest expense	-482.00 сая	-432.00 сая	-406.00 сая	-403.00 сая
Net interest expenses	-321.00 сая	-284.00 сая	-302.00 сая	-302.00 сая
Depreciation and amortization charges	-	-	-	-
EBITDA	4.91 тэрбум	4.54 тэрбум	4.41 тэрбум	5.08 тэрбум
Gain or loss from assets sale	-9.00 сая	-	-34.00 сая	-142.00 сая

Finance

Ask anything